Diagnostic criteria and updated classification of MCAS and other MCAD
Peter Valent (Vienna, Austria)
8.30 am
Role of mastocytosis in anaphylaxis: data from the European anaphylaxis registry
Veronika Höfer (Berlin, Germany)
8.45 am
Drug-induced anaphylaxis in mastocytosis: findings from large cohorts
Michiel Beyens (Antwerp, Belgium)
9.00 am
Challenges in drug and hymenoptera venom hypersensitivity diagnosis and management in mastocytosis
Mariana C. Castells (Boston, USA)
9.15 am
Diagnostic work up and management of anaphylaxis in mastocytosis
Hanneke Oude Elberink (Groningen, The Netherlands)
9.30 am
Prevalence, diagnosis, and managment of MCAS: an update
Theo Gülen (Stockholm, Sweden)
9.45 am
Coffee Break
10.05 am - 12.00 pm
Session IX: Treatment Aims, Targeted Treatment and Unmet Needs in Advanced and Non-Advanced systemic mastocytosis
Chairs: Deepti Radia (London, U.K.) & Juliana Schwaab (Mannheim, Germany)
10.05 am
Best supportive care for the treatment of mast cell mediator-related symptoms in mastocytosis
Massimo Triggiani (Salerno, Italy)
10.25 am
Update on targeted treatment for non-advanced systemic mastocytosis
Karin Hartmann (Basel, Switzerland)
10.45 am
Update on targeted treatment for advanced systemic mastocytosis
Jason Gotlib (Stanford, USA)
11.05 am
Altered immune profiles and ultra-sensitive blood assays in the diagnostic work-up of systemic mastocytosis
Alberto Orfao (Salamanca, Spain)
11.25 am
Aims, needs, and future perspectives in the treatment of non-advanced systemic mastocytosis
Vito Sabato (Antwerp, Belgium)
11.45 am
Development of a mast cell depleting antibody for the treatment of mastocytosis
William Worrall (Toulouse, France)
12.00 pm
Lunch Break
12.50 pm - 2.35 pm
Session X: Late Breaking Updates
Chairs: Knut Brockow (Munich, Germany) & Lawrence B. Schwartz (Richmond, USA)
12.50 pm
Allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a retrospective analysis of the DRST and GREM registries
Jens Panse (Aachen, Germany)
1.05 pm
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: best practice recommendations
Deepti Radia (London, U.K.)
1.20 pm
Allo-HSCT in advanced systemic mastocytosis: the Vienna experience
Karoline V. Gleixner (Vienna, Austria)
1.35 pm
Cladribine improves cutaneous manifestations and quality of life of patients with mastocytosis
Stéphane Barete (Paris, France)
1.50 pm
CRISPR/Cas engineered iPSCs: a novel cell-based model for mastocytosis
Yanyan Luo (Berlin, Germany)
2.05 pm
The synthetic triterpenoids bardoxolone methyl and omaveloxolone synergize with KITD816V-targeting drugs in counteracting the survival of neoplastic cells in advanced systemic mastocytosis
Max V. John (Vienna, Austria)
2.20 pm
Advancements in highly sensitive detection of KIT D816V mutation in blood: transforming diagnostic practices for systemic mastocytosis
Rudi Steffensen (Aalborg, Denmark)
2.35 pm
Summary of Day 3 and Closing Remarks
3.00 pm - 4.00 pm
Hybrid Session with online stream open for registered patients
3.00 pm
Post-ECNM Meeting and Round Table Discussion
3.00 pm
Summary and Highlights of ECNM 2024
Karin Hartmann & Jens Panse
3.15 pm
Round Table Discussion
Panelists: Knut Brockow, Melody Carter, Mariana C. Castells, Karin Hartmann, Jens Panse, Vito Sabato; Moderator: Frank Siebenhaar